Convalescence from prototype SARS-CoV-2 protects Syrian hamsters from disease caused by the Omicron variant

Ryan KA, Watson RJ, Bewley KR, Burton C, Carnwell O, Cavell BE, Challis A, Coombes NS, Emery K, Fell R, Fotheringham SA, Gooch KE, Gowan K, Handley A, Harris BJ, Humphries R, Johnson R, Knott D, Lister S, Morley D, Ngabu D, Osman KL, Paterson J, Penn EJ, Pullan ST, Richards KS, Shaik I, Summers S, Thomas SJ, Weldon T, Wiblin NR, Vipond R, Hallis B, Funnell S, Hall . (2023)

PLOS Pathogens, 19(4), e1011293

The mutation profile of the SARS-CoV-2 Omicron variant poses a concern for naturally acquired and vaccine-induced immunity. We investigated the ability of prior infection with an early SARS-CoV-2, 99.99% identical to Wuhan-Hu-1, to protect against disease caused by the Omicron variant. We established that infection with Omicron in naïve Syrian hamsters resulted in a less severe disease than a comparable dose of prototype SARS-CoV-2 (Australia/VIC01/2020), with fewer clinical signs and less weight loss. We present data to show that these clinical observations were almost absent in convalescent hamsters challenged with the same dose of Omicron 50 days after an initial infection with Australia/VIC01/2020. The data provide evidence for immunity raised against prototype SARS-CoV-2 being protective against Omicron in the Syrian hamster model. Further investigation is required to conclusively determine whether Omicron is less pathogenic in Syrian hamsters and whether this is predictive of pathogenicity in humans.

PLOS Pathogens, 19(4), e1011293

View Publication